These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20361265)

  • 1. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
    Le Tourneau C; Diéras V; Tresca P; Cacheux W; Paoletti X
    Target Oncol; 2010 Mar; 5(1):65-72. PubMed ID: 20361265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation methods in phase I cancer clinical trials.
    Le Tourneau C; Lee JJ; Siu LL
    J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
    Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
    Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing landscape of phase I trials in oncology.
    Wong KM; Capasso A; Eckhardt SG
    Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation oncology drug development: opportunities and challenges.
    Gutierrez ME; Kummar S; Giaccone G
    Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
    Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
    Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.
    Dorris K; Liu C; Li D; Hummel TR; Wang X; Perentesis J; Kim MO; Fouladi M
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27654490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development in oncology: classical cytotoxics and molecularly targeted agents.
    Kummar S; Gutierrez M; Doroshow JH; Murgo AJ
    Br J Clin Pharmacol; 2006 Jul; 62(1):15-26. PubMed ID: 16842375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drug approvals in oncology.
    Kurzrock R; Kantarjian HM; Kesselheim AS; Sigal EV
    Nat Rev Clin Oncol; 2020 Mar; 17(3):140-146. PubMed ID: 32020042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early phase clinical trials to identify optimal dosing and safety.
    Cook N; Hansen AR; Siu LL; Abdul Razak AR
    Mol Oncol; 2015 May; 9(5):997-1007. PubMed ID: 25160636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
    Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
    J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular toxicity of targeted therapies.
    Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
    J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.
    Nikanjam M; Liu S; Yang J; Kurzrock R
    Oncologist; 2017 May; 22(5):576-584. PubMed ID: 28424323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approving molecularly targeted drugs: different approval processes for cytotoxic agents.
    Sasahara Y; Narimatsu H; Fukao A; Yoshioka T
    Int J Clin Oncol; 2016 Oct; 21(5):1004-1013. PubMed ID: 27105626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.